Crizotinib (PF-02341066) | ALK/c-Met/ROS1阻害剤 | MedChemExpress
Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer
Crizotinib inhibits activation of MET pathway caused by MET extracellular SEMA domain duplication - Lung Cancer
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration | Nature Medicine
Crizotinib exhibits antitumor activity by targeting ALK signaling not c-MET in pancreatic cancer. - Abstract - Europe PMC
![Chidamide increases the sensitivity of Non-small Cell Lung Cancer to Crizotinib by decreasing c-MET mRNA methylation [Abstract]](https://www.ijbs.com/v16/p2595/toc.jpg "Chidamide increases the sensitivity of Non-small Cell Lung Cancer to Crizotinib by decreasing c-MET mRNA methylation [Abstract]")
Chidamide increases the sensitivity of Non-small Cell Lung Cancer to Crizotinib by decreasing c-MET mRNA methylation [Abstract]
JCM | Free Full-Text | The Role of MET Inhibitor Therapies in the Treatment of Advanced Non-Small Cell Lung Cancer | HTML
Crizotinib inhibits c-MET activation and shows in-vitro efficacy in CRC... | Download Scientific Diagram
Crizotinib hydrochloride | c-Met 阻害剤
Crizotinib is an Orally Active, ATP-Competitive ALK and c-Met inhibitor - Network of Cancer Research
CRZ in MET-Rearranged NSCLC - Lung Cancer - 2016 American Society of Clinical Oncology Annual Meeting - Oncology - Clinical Care Options
Safety and Tolerability of c-MET Inhibitors in Cancer | SpringerLink
Crizotinib, a MET inhibitor, prevents peritoneal dissemination in pancreatic cancer
Characterization of MET exon 14 alteration and association with clinical outcomes of crizotinib in Chinese lung cancers - Lung Cancer
cに応じられた阻害 | c-Met Inhibition
MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) Shows Differential Antitumor Effects in Non-small Cell Lung Cancer According to MET Alterations - Journal of Thoracic Oncology
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration | Nature Medicine
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration | Nature Medicine
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - Cancer Treatment Reviews
Crizotinib-resistant MET mutations in gastric cancer patients are sensitive to type II tyrosine kinase inhibitors | Future Oncology
PLOS ONE: Ability of the Met Kinase Inhibitor Crizotinib and New Generation EGFR Inhibitors to Overcome Resistance to EGFR Inhibitors
Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation. | Semantic Scholar
Crizotinib inhibits migration and expression of ID1 in MET-positive lung cancer cells: implications for MET targeting in oncology | Future Oncology
ADAM17-Dependent c-MET-STAT3 Signaling Mediates Resistance to MEK Inhibitors in KRAS Mutant Colorectal Cancer: Cell Reports
PLOS ONE: Ability of the Met Kinase Inhibitor Crizotinib and New Generation EGFR Inhibitors to Overcome Resistance to EGFR Inhibitors
Expanding treatment options in NSCLC patients with rare mutations: ALK, ROS1, MET, BRAF - memoinOncology
